bevacizumab,panitumumab
amgen,roche,takeda
['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
paradigm showed panitumumab+mfolfox6 outperforms bev + mfolfox6 for os endpoint on left sided mcrc. do we need to be worried about the early crossing of survival curves and claims of superiority? plenary session off to a great start #asco22 
Chief Fellow @PennCancer. GI Cancers. MSCE Student @UPennDBEI. Innovation Fellow @PC3Innovation. Former @UTSWIMchief. Lucas’ dad forever. No COI/views own